Portal de investigación
INFUSION DE CELULAS NATURAL KILLER ALOREACTIVAS O ESTIMULADAAS CON IL-15 EX VIVO TRAS TRASPLANTE HAPLOIDENTICO DE PROGENITORES HEMATOPOYETICOS EN PACIENTES PEDIATRICOS CON NEOPLASIAS HEMATOLOGICAS (PHINK).
Datos básicos
- Protocolo:
- PHINK-01/2019
- EUDRACT:
- 2019-000911-10
- NCT:
- Centro:
- HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE
- Año de incio:
- 2021
- Año de finalización:
- 2023
Documentos
- No hay documentos
Participantes
Financiadores - Promotores
Resultados del Ensayo Clínico
A Randomized Comparison of Liposomal Daunorubicin/Daunorubicin Combined with Low-Dose Cytarabine and Etoposide or High-Dose Cytarabine and Fludarabine in Induction Treatment of Pediatric AML Using MRD- Based Risk Stratification in the NOPHO-DBH AML 2012 Protocol
De Moerloose, Barbara; (...); Abrahamsson, Jonas
Meeting Abstract. 10.1182/blood-2023-187251. 2023
ANALYSIS OF TREATMENT AND OUTCOME OF RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA ACCORDING TO IMMUNOPHENOTYPE IN SPAIN
Ramos Elbal, Eduardo; (...); Fuster, Jose Luis
Meeting Abstract. 2023
Blinatumomab to improve the outcome of children with relapsed B-cell acute lymphoblastic leukemia.
Fuster JL; (...); Dapena JL
Letter. 10.1007/s12094-021-02590-0. 2021
Casuística de tumor miofibroblástico inflamatorio en centro terciario.
Martínez Navarro G; (...); Fernández Navarro JM
Case Reports. 10.1016/j.anpedi.2020.12.007. 2021
Casuistics of inflammatory myofibroblastic tumor in a tertiary center.
Martínez Navarro G; (...); Fernández Navarro JM
Case Reports. 10.1016/j.anpede.2020.12.016. 2021
Comprehensive detection of CRLF2 alterations in acute lymphoblastic leukemia: a rapid and accurate novel approach.
Gil, Jose Vicente; (...); Barragan, Eva
Article. 10.3389/fmolb.2024.1362081. 2024
Chip-AML22 Master Protocol: An Open-Label Clinical Trial in Newly Diagnosed Pediatric De Novo Acute Myeloid Leukemia (AML) Patients Including a Linked Phase II Trial with Quizartinib in FLT3-ITD/ NPM1wt Patients - a Study By the NOPHO-DB-SHIP Consortium
Kaspers, Gertjan J. L.; (...); Pronk, Cornelis Jan
Meeting Abstract. 10.1182/blood-2023-181792. 2023
Defibrotide in Hematopoietic Stem Cell Transplant: An Study of Grupo Espanol De Trasplante Hematopoyetico (GETH) And Grupo Espanol De Trasplante De Medula En NinOS (GETMON)
Vicent, MG; (...); Diaz, MA
Meeting Abstract. 2020
Defibrotide In Hematopoietic Stem Cell Transplantation: A Multicenter Survey Study Of The Spanish Hematopoietic Stem Cell Transplantation Group (Geth).
González Vicent M; (...); Díaz MÁ
Article. 10.1111/ejh.13618. 2021
ECLIM-SEHOP: how to develop a platform to conduct academic trials for childhood cancer.
Juan-Ribelles A; (...); Fernández-Teijeiro A
Article. 10.1007/s12094-024-03445-0. 2024
Experience of the Spanish Group for Hematopoietic Transplantation (GETMON-GETH) in allogenic Hematopoietic stem cell Transplantation in Philadelphia acute lymphoblastic leukemia.
Galán Gómez V; (...); Pérez-Martínez A
Article. 10.1016/j.anpede.2021.02.016. 2022
Experiencia del Grupo Español de Trasplante Hematopoyético (GETMON-GETH) en el trasplante alogénico de progenitores hematopoyéticos en leucemia aguda linfoblástica Philadelphia.
Galán Gómez V; (...); Pérez-Martínez A
Article. 10.1016/j.anpedi.2021.02.015. 2021
Germline Predisposition to Pediatric Cancer, from Next Generation Sequencing to Medical Care.
Gargallo P; (...); Cañete A
Article. 10.3390/cancers13215339. 2021
Haploidentical vs. HLA-matched donor hematopoietic stem-cell transplantation for pediatric patients with acute lymphoblastic leukemia in second remission: A collaborative retrospective study of the Spanish Group for Bone Marrow Transplantation in Children (GETMON/GETH) and the Spanish Childhood Relapsed ALL Board (ReALLNet).
Moreno, Celia; (...); Fuster, Jose Luis
Article. 10.3389/fped.2023.1140637. 2023
Helpful Criteria When Implementing NGS Panels in Childhood Lymphoblastic Leukemia.
Vega-Garcia N; (...); Camós M
Article. 10.3390/jpm10040244. 2020
Hematopoietic stem cell transplantation in children with chronic granulomatous disease: the Spanish experience.
Alonso García L; (...); Diaz de Heredia Rubio C
Article. 10.3389/fimmu.2024.1307932. 2024
Management of Hyperleukocytosis in Pediatric Acute Myeloid Leukemia Using Immediate Chemotherapy without Leukapheresis, in Protocol NOPHO-DBH AML-2012
Zeller, Bernward; (...); Abrahamsson, Jonas
Meeting Abstract. 10.1182/blood-2023-184921. 2023
Management of hyperleukocytosis in pediatric acute myeloid leukemia using immediate chemotherapy without leukapheresis: results from the NOPHO-DBH AML 2012 Protocol.
Zeller B; (...); Abrahamsson J
Article. 10.3324/haematol.2024.285285. 2024
Measurable Residual Disease and Fusion Partner Independently Predict Survival and Relapse Risk in Childhood KMT2A-Rearranged Acute Myeloid Leukemia: A Study by the International Berlin-Frankfurt-Münster Study Group.
van Weelderen, Romy E; (...); Kaspers GJL
Article. 10.1200/JCO.22.02120. 2023
Measurable Residual Disease Assessed by Flow-Cytometry Is a Stable Prognostic Factor for Pediatric T-Cell Acute Lymphoblastic Leukemia in Consecutive SEHOP Protocols Whereas the Impact of Oncogenetics Depends on Treatment.
Vega-García N; (...); Camós M
Article. 10.3389/fped.2020.614521. 2021
Mitoxantrone Versus Liposomal Daunorubicin in Induction of Pediatric AML With Risk Stratification Based on Flow Cytometry Measurement of Residual Disease.
Tierens, Anne; (...); Abrahamsson, Jonas
Article. 10.1200/JCO.23.01841. 2024
Optimized Cytogenetic Risk-Group Stratification of KMT2A-Rearranged Pediatric Acute Myeloid Leukemia.
van Weelderen, Romy E.; (...); Kaspers, Gertjan J. L.
Article. 10.1182/bloodadvances.2023011771. 2024
Outcome after HSCT in Children with JMML from a Historical Point of View
Duarte, ML; (...); Vazquez, GP
Meeting Abstract. 2020
Outcomes of Unmanipulated Haploidentical Transplantation Using Post-Transplant Cyclophosphamide (PT-Cy) in Pediatric Patients With Acute Lymphoblastic Leukemia
Ruggeri, A; (...); Corbacioglu, S
Article. 10.1016/j.jtct.2021.01.016. 2021
Treosulfan-Based Conditioning Regimen In Pediatric Hematopoietic Stem Cell Transplantation: A Retrospective Analysis on Behalf of the Spanish Group for Hematopoietic Transplantation and Cellular Therapy (GETH-TC).
Galán V; (...); Pérez-Martínez A
Article. 10.1016/j.jtct.2023.08.016. 2023
Use of Eculizumab in Pediatric Patients with High-Risk Transplantation-Associated Thrombotic Microangiopathy: Outcomes and Risk Factors Associated with Response and Survival. A Retrospective Study on Behalf of the Spanish Group for Hematopoietic Transplantation and Cellular Therapy (GETH-TC).
Benítez Carabante MI; (...); Diaz-de-Heredia C
Article. 10.1016/j.jtct.2024.03.019. 2024